This article was previously published with some errors. There was a discrepancy between the abstract and the full text regarding the number of patients on continuous hydroxychloroquine therapy over 5 ...

Introduction Anifrolumab (Saphnelo) is approved for adult patients with moderate-severe systemic lupus erythematosus (SLE). Considering its commercialisation in Spain in 2023, observational studies ...

Systemic lupus erythematosus (SLE) is a clinically and immunologically heterogeneous autoimmune disease that can be challenging to diagnose, especially in its early stages. Although developed in the ...

A key lupus outcome measure is the assessment of damage, which is considered as a separate domain to disease activity and health related quality of life and has been shown to independently predict ...

Bone involvement is a common cause of morbidity and disability in systemic lupus erythematosus (SLE). 1 This is both a consequence of the disease itself and treatments, including steroids.2 As ...

Despite advancements in lupus management over the past two decades, infection remains a significant cause of morbidity and mortality among patients with systemic lupus erythematosus (SLE). 1 2 Various ...

Hemophagocytic lymphohistiocytosis (HLH) is a well-recognised complication of systemic lupus erythematosus (SLE). In one small case series, HLH was noted in approximately 5% of patients with lupus. 1 ...

PRIME TIME SESSION: (HYBRID) PART I: BABY YOU CAN DRIVE MY CAR-T CELLS ... AND OTHER NOVEL THERAPIES ...

Background Childhood-onset systemic lupus erythematosus (cSLE) is an autoimmune disease, which causes systemic involvement, including within the central nervous system (CNS). Since biomarkers for ...

O33 Longitudinal assessment of biomarkers in NOBILITY, a randomized, phase II clinical trial of obinutuzumab for treatment of proliferative lupus nephritis ...

LBP1 Interim results of an open-label, multicentre, Phase 1/2 study to assess YTB323 (rapcabtagene autoleucel), a CAR T-cell therapy, for severe refractory systemic lupus erythematosus ...

Objective The clinic of systemic lupus erythematosus (SLE) potentially leads to social isolation, inactivity, muscle loss and depression. In addition to medical treatment, the current EULAR ...